Core Insights - Korro Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines through RNA editing for both rare and prevalent diseases [3] Company Overview - Korro Bio utilizes a proprietary RNA editing platform to create a portfolio of differentiated programs aimed at harnessing the body's natural RNA editing process, allowing for precise and transient single base edits [3] - The company aims to enhance the precision and tunability of genetic medicines by editing RNA instead of DNA, which may lead to increased specificity and improved long-term tolerability [3] - Korro plans to leverage its proprietary platform along with established delivery modalities, manufacturing expertise, and regulatory pathways of approved oligonucleotide drugs to bring its medicines to patients [3] Upcoming Events - Ram Aiyar, Ph.D., CEO and President of Korro, will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 11:50 a.m. ET [1] - Todd Chappell, COO, will participate in one-on-one investor meetings at the same conference [1]
Korro to Present at the TD Cowen 45th Annual Health Care Conference